CA Patent

CA2505316C — Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor

Assigned to Ablynx NV · Expires 2014-08-05 · 12y expired

What this patent protects

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides.

USPTO Abstract

The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides.

Drugs covered by this patent

dabigatran-etexilate-mesylate (DABIGATRAN ETEXILATE MESYLATE)

Patent Metadata

Patent number: CA2505316C
Jurisdiction: CA
Classification: —
Expires: 2014-08-05
Drug substance claim: No
Drug product claim: No
Assignee: Ablynx NV
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.